MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

Phase 2
Completed
Conditions
Onychomycosis
First Posted Date
2008-05-19
Last Posted Date
2019-02-21
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT00680160
Locations
🇺🇸

J&S Studies, Bryan, Texas, United States

Study of Different Doses of a Novel Treatment for Onychomycosis

Phase 2
Completed
Conditions
Distal, Subungual Onychomycosis
Interventions
Drug: AN2690, 2.5%
Drug: AN2690, 5%
Drug: AN2690, 7.5%
Drug: AN2690 Solution Vehicle
First Posted Date
2008-05-19
Last Posted Date
2018-12-12
Lead Sponsor
Pfizer
Target Recruit Count
159
Registration Number
NCT00679965
Locations
🇲🇽

Unidad de Investigación en Salud (UIS), Chihuahua, Mexico

🇲🇽

Hospital Universitario Dr. José Eleuterio González, Monterrey, Mexico

🇲🇽

Instituto Dermatologico Jalisciense, Guadalajara, Mexico

and more 6 locations

Cumulative Irritation Test

Phase 1
Completed
Conditions
Onychomycosis
Interventions
Drug: AN2690
Other: AN2690 Solution, Vehicle
Other: Sodium Lauryl Sulfate, 0.5%
First Posted Date
2008-05-19
Last Posted Date
2019-04-09
Lead Sponsor
Pfizer
Target Recruit Count
37
Registration Number
NCT00680095
Locations
🇺🇸

The Education and Research Foundation, Inc., Lynchburg, Virginia, United States

Safety and Efficacy Evaluation of Topically Applied AN2690 Solutions for Subjects With Onychomycosis

Phase 2
Completed
Conditions
Onychomycosis
Interventions
Drug: AN2690
First Posted Date
2008-05-19
Last Posted Date
2018-02-20
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT00680134
Locations
🇺🇸

Academic Dermatology Associates, Albuquerque, New Mexico, United States

🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

DermResearch, Inc., Austin, Texas, United States

and more 4 locations

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME II)

Phase 2
Completed
Conditions
Onychomycosis
First Posted Date
2008-05-19
Last Posted Date
2018-02-20
Lead Sponsor
Pfizer
Target Recruit Count
20
Registration Number
NCT00679601
Locations
🇺🇸

J&S Studies, Bryan, Texas, United States

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: CP-690,550
Drug: Placebo
First Posted Date
2008-05-15
Last Posted Date
2012-12-19
Lead Sponsor
Pfizer
Target Recruit Count
197
Registration Number
NCT00678210
Locations
🇨🇦

Pfizer Investigational Site, Quebec, Canada

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Phase 2
Withdrawn
Conditions
Breast Cancer
Interventions
Drug: CP-751,871
Drug: Docetaxel
First Posted Date
2008-05-15
Last Posted Date
2015-05-04
Lead Sponsor
Pfizer
Registration Number
NCT00678626

Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa

Phase 2
Completed
Conditions
Malaria, Falciparum
Interventions
First Posted Date
2008-05-15
Last Posted Date
2014-06-26
Lead Sponsor
Pfizer
Target Recruit Count
361
Registration Number
NCT00677833
Locations
🇲🇱

Pfizer Investigational Site, Sikasso, West Africa, Mali

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Phase 3
Completed
Conditions
Kidney Neoplasms
Interventions
First Posted Date
2008-05-15
Last Posted Date
2019-01-09
Lead Sponsor
Pfizer
Target Recruit Count
723
Registration Number
NCT00678392
Locations
🇺🇸

LAC-USC Medical Center, Los Angeles, California, United States

🇺🇸

Ronald Regan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States

and more 231 locations

Topical CP-690,550 For Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: CP-690,550
Drug: Placebo Vehicle
First Posted Date
2008-05-15
Last Posted Date
2020-12-31
Lead Sponsor
Pfizer
Target Recruit Count
81
Registration Number
NCT00678561
Locations
🇨🇦

NewLab Clinical Research Inc., St. John's, Newfoundland and Labrador, Canada

🇺🇸

Central Dermatology, PC, Saint Louis, Missouri, United States

🇺🇸

Dermatology Consulting Services, High Point, North Carolina, United States

and more 17 locations
© Copyright 2025. All Rights Reserved by MedPath